Delivery Order SPE2DB20D1109-SPE2DB24FM97F
- Not listed
- This federal contract award, valued at $1,803.16, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for 4,559,034,566 units of Ondansetron HCL 4 mg tablets, a medication used to prevent nausea and vomiting. The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support...
- This federal contract award, valued at $19,223.75, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,566,816,308 units of Ondansetron HCL 8 mg tablets, a medication used to prevent nausea and vomiting. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of January 2, 2025. It is not designated as a...
- This federal contract award, valued at $1,659.48, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4,561,731,832 units of the pharmaceutical drug Ondansetron ODT 4 MG Tablet, a medication used to treat nausea and vomiting. The contract has an ultimate completion date of August 8, 2023 and is a firm fixed-price delivery order. It is not associated with any set-aside requirements, indicating full...
- This federal contract award, valued at $19,368.22, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,563,416 units of Ondansetron HCL 4 mg tablets, a medication commonly used to treat nausea and vomiting. The contract is a firm fixed-price Delivery Order with a completion date of January 24, 2024. It is not designated as a set-aside contract....
- This federal contract award, valued at $11,863.60, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,561,986,378 units of Ondansetron HCL 8 mg tablets, a medication used to prevent nausea and vomiting. The contract, which has a firm fixed price, is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA...
- This federal contract award, valued at $17,009.53, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,565,665,266 units of Ondansetron HCL 4 mg tablets, a medication used to prevent nausea and vomiting. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of September 4, 2024. It is not designated as a...
- This federal contract award, valued at $12,458.37, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,567,678 units of Ondansetron HCL 4 mg tablets, a medication used to treat nausea and vomiting. The contract has an ultimate completion date of March 25, 2025 and is a Firm Fixed Price Delivery Order with no set-aside designation, indicating open competition....
- This federal contract award, valued at $10,624.15, was issued to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., by the Defense Logistics Agency (DLA). The contract is a delivery order for the supply of 4,559,022,633 units of 4 mg Ondansetron HCl tablets, a medication used to prevent nausea and vomiting. The contract has a firm fixed price pricing type and an ultimate completion date of November 8, 2022. It is not designated as a set-aside contract....
- This federal contract award, valued at $15,158.08, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,560,679,329 units of Ondansetron ODT 4 mg tablets, a medication used to treat nausea and vomiting. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop...
- This federal contract award, valued at $2,712.68, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,566,510,655 units of 4 mg Ondansetron HCL tablets, a medication used to prevent nausea and vomiting. This is a firm fixed-price delivery order contract with a completion date of November 22, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB24FM97FDelivery Order
This federal contract award, valued at $4,615.81, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4,562,586,918 units of Ondansetron HCL 8 mg tablets, a pharmaceutical product used to treat nausea and vomiting. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of October 25, 2023. It is not designated as a set-aside contract. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.6k | 10/24/23 |